DODA ( DEC ) ( DE ) DE ( DE ) ( DE ) ( DE ) ( DE )			APPLICATION NO.:	10/766,755	ATTY. DOCKET NO.: A0752.70001US01	
FORM PTO-1449/A and B (modified PTO/SB/08)				FILING DATE:	FILING DATE: January 28, 2004 CONFIRMATION NO.: 2264	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT:	Gregory Stahl et al.		
Sheet 1 of 2				GROUP ART UNIT:	1644	EXAMINER: François P. Vandervegt

ILS PATENT DOCUMENTS

	OID THE STATE OF T								
	Examiner's Initials #	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication or Issue of Cited Document			
		No.	Number	Kind Code	Document	MM-DD-YYYY			
			7 273 925		Stahl et al	09-25-2007			

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite	Foreign Patent Document			Name of Patentee or Applicant of Cited	Date of Publication of	Translation	
	No.	Office/ Country	Number	Kind Code	Document	Cited Document MM-DD-YYYY	(Y/N)	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] Alexion Pharmaceuticals: Product profiles: Myocardial infarction.	
		http://www.alexionpharm.com/products/mi.cfm, Accessed November 8, 2000. 1 page.	1
		[No Author Listed] Alexion Pharmaceuticals: Complement inhibitors.	
	1	http://www.alexionpharm.com/techplat/complement.cfm. Accessed November 8, 2000. 2 pages.	
		[No Author Listed]. Alexion Pharmaceuticals and the Brigham and Women's Hospital form	1
		collaboration to develop novel anti-inflammatory antibody. Press release dated February 15, 2000.	ł
		http://www.alexionpharm.com/news/sub_press.cfm?prid=159&selectyear=2000. Accessed	
		November 8, 2000. 2 pages.	
		[No Author Listed] Alexion Pharmaceuticals & Brigham and Women's Hospital scientists	
		demonstrate new pathway for complement activation in cardiovascular disease. Press release dated	
		May 3, 2000. http://www.alexionpharm.com/news/sub_press.cfm?prid=172&selectyear=2000.	
		Accessed November 8, 2000. 3 pages.	
		[No Author Listed] Scientific study published in Journal of Clinical Investigation demonstrates	
		terminal complement activation causes kidney damage during ischemia and reperfusion. Press	
		release dated May 15, 2000.	1
	ł	http://www.alexionpharm.com/news/sub_press.cfm?prid=173&selectyear=2000. Accessed	
		November 8, 2000. 3 pages.	
		[No Author Listed] Read a story about complement in The Economist. Letter to shareholders and	
		interested parties from Leonard Bell, MD, President and CEO of Alexion Pharmaceuticals, Inc.	
		http://www.alexionpharm.com/news/sub_press.cfm?prid=174&selectyear=2000. Accessed	
		November 8, 2000. 2 pages.	
		JANEWAY et al., 3-19 (last paragraph) to 3-20. In Immunobiology. Garland Press. 2 pages.	
		JANEWAY et al., The distribution and functions of immunoglobulin isotypes. In Immunobiology.	i
		Garland Press, 2 pages.	
		JANEWAY et al., 13-11 (last 3 paragraphs) to 13-13 (first 4 lines of second paragraph). In	
		Immunobiology. Garland Press. 3 pages.	
		JANEWAY et al., 13-6 (end of section) to 13-7 (first four paragraphs). In Immunobiology, Third	
		Edition. Garland Press. 2 pages.	l

EXAMINER:	DATE CONSIDERED:

<sup>&</sup>lt;sup>6</sup> EXAMINER: Initial if reference considered, whether or noteitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICATION NO.: 10/766,755 ATTY. DOCKET NO		ATTY. DOCKET NO.: A0752.70001US01
			FILING DATE:	January 28, 2004	CONFIRMATION NO.: 2264
			APPLICANT:	Gregory Stahl et al.	
Sheet 2 of 2		GROUP ART UNIT:	1644	EXAMINER: François P. Vandervegt	

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 (CFR § 1.98 and 1287OG) (63. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless I) such copies were provided in an IDS in an earlier application that complies with 37 CFR § 1.98, and 2) the earlier application is relied upon for an earlier filing due under 35 U.S.C. § 120.]

EXAMINER:	DATE CONSIDERED:

<sup>&</sup>quot;EXAMINER: Initial if reference considered, whether or note intion is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.